Zusammenfassung
Die Schwere der Symptome bei der benignen Prostatahyperplasie (BPH) bestimmt die Indikation zur Therapie. Durch die Zusammenschau der jeweiligen Symptome mit dessen Schweregrad und Verlauf sowie den erhobenen Untersuchungsbefunden können eine BPH gegenüber anderen Erkrankungen abgegrenzt und verschiedene therapeutische Herangehensweisen ermöglicht werden. Für die Wahl des Therapiekonzeptes muss die Erwartungshaltung des Patienten mit dem Wunsch einer Symptomreduzierung und die Risikoabwägung desselben betrachtet werden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. [No authors listed] J Urol. 1993 Nov; 150(5 Pt 2):1696–700. https://doi.org/10.1016/s0022-5347(17)35870-6. PMID: 7692104
Alken CE, Staeler W (1973) Klinische Urologie. Georg Thieme
Barqawi AB, Sullivan KF, Crawford ED et al (2011) Methods of developing UWIN, the modified American Urological Association symptom score. J Urol 186:940–944. https://doi.org/10.1016/j.juro.2011.04.057
Barry MJ, Fowler FJ, O’Leary MP et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148:1549–1557; discussion 1564. https://doi.org/10.1016/s0022-5347(17)36966-5
Chughtai B, Forde JC, Thomas DDM et al (2016) Benign prostatic hyperplasia. Nat Rev Dis Primers 2:16031. https://doi.org/10.1038/nrdp.2016.31
D’Silva KA, Dahm P, Wong CL (2014) Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. JAMA 312:535–542. https://doi.org/10.1001/jama.2014.5555
Donovan JL, Abrams P, Peters TJ et al (1996) The ICS-’BPH’ Study: the psychometric validity and reliability of the ICSmale questionnaire. Br J Urol 77:554–562. https://doi.org/10.1046/j.1464-410x.1996.93013.x
Donovan JL, Peters TJ, Abrams P et al (2000) Scoring the short form ICSmaleSF questionnaire. International Continence Society. J Urol 164:1948–1955
Douenias R, Rich M, Badlani G et al (1991) Predisposing factors in bladder calculi. Review of 100 cases. Urology 37:240–243. https://doi.org/10.1016/0090-4295(91)80293-g
Gratzke C, Bachmann A, Descazeaud A et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including Benign prostatic obstruction. Eur Urol 67:1099–1109. https://doi.org/10.1016/j.eururo.2014.12.038
Jacobsen SJ, Jacobson DJ, Girman CJ et al (1997) Natural history of prostatism: risk factors for acute urinary retention. J Urol 158:481–487. https://doi.org/10.1016/s0022-5347(01)64508-7
Lepor H (2005) Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol 7(Suppl 7):S3–S11
McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398. https://doi.org/10.1056/NEJMoa030656
McVary KT (2003) Clinical evaluation of benign prostatic hyperplasia. Rev Urol 5(Suppl 4):S3–S11
Miernik A, Gratzke C (2020) Current Treatment for Benign Prostatic Hyperplasia. Dtsch Arztebl Int 117:843–854. https://doi.org/10.3238/arztebl.2020.0843
Millán-Rodríguez F, Errando-Smet C, Rousaud-Barón F et al (2004) Urodynamic findings before and after noninvasive management of bladder calculi. BJU Int 93:1267–1270. https://doi.org/10.1111/j.1464-410X.2004.04815.x
Oelke M, Kirschner-Hermanns R, Thiruchelvam N, Heesakkers J (2012) Can we identify men who will have complications from benign prostatic obstruction (BPO)?: ICI-RS 2011. Neurourol Urodyn 31:322–326. https://doi.org/10.1002/nau.22222
Peters TJ, Donovan JL, Kay HE et al (1997) The International Continence Society “Benign Prostatic Hyperplasia” study: the botherosomeness of urinary symptoms. J Urol 157:885–889
Rule AD, Jacobson DJ, Roberts RO et al (2005) The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int 67:2376–2382. https://doi.org/10.1111/j.1523-1755.2005.00344.x
Schou J, Poulsen AL, Nordling J (1993) The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH. Scand J Urol Nephrol 27:489–492. https://doi.org/10.3109/00365599309182282
Vahlensieck W Vahlensieck W (1983) Epidemiologie der Prostatahyperplasie. In: Helpap B, Senge Th, Vahlensieck W (Hrsg) Die Prostata, Bd I, pmi-Verlag, Frankfurt a. M., S 1–8
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature
About this chapter
Cite this chapter
Becker, B. (2022). Symptomatologie. In: Netsch, C., Gross, A.J. (eds) Benignes Prostatasyndrom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-64334-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-662-64334-1_4
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-64333-4
Online ISBN: 978-3-662-64334-1
eBook Packages: Medicine (German Language)